Paul Lockman , PhD, BSN

Professor, Benedum Fellow and the Mylan Endowed Chair

Organization:

West Virginia University School of Pharmacy

Department:

Pharmaceutical Sciences

Classification:

Fellow

Senior Associate Dean for Research and Strategic Initiatives, School of Pharmacy

Organization:

West Virginia University School of Pharmacy

Department:

Office of the Dean

Classification:

Admin

Professor

Organization:

West Virginia University School of Medicine

Department:

Department of Neuroscience

Classification:

Faculty

Member

Organization:

West Virginia University WVU Cancer Institute

Department:

WVU Cancer Institute Research Programs

Classification:

Faculty

Professor

Organization:

West Virginia University School of Medicine

Department:

Rockefeller Neuroscience Institute (SOM)

Classification:

Faculty

• PhD, Texas Tech University

[2018]

• Shah N, Mohammad AS, Saralkar P, Sprowls SA, Vickers SD, John D, Tallman RM, Lucke-Wold BP, Jarrell KE, Pinti MV, Nolan RL, Lockman PR.  Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res. Accepted 27 Mar 2018. 
• Mohammad AS, Griffith JI, Adkins CE, Shah N, Sechrest E, Dolan EL, Terrell-Hall TB, Hendriks BS, Lee H, Lockman PR (2018). Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer. Pharm Res. 2018 Jan 9;35 (2):31.

• Terrell-Hall TB, Nounou MI, El-Amrawy F, Griffith JIG, Lockman PR (2017). Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer. Oncotarget, 8(48):83734-83744. PMCID: PMC5663550
• Logsdon AF, Lucke-Wold BP, Turner RC, Li X, Adkins CE, Mohammad AS, Huber JD, Rosen CL, Lockman PR (2017). A mouse model of focal vascular injury induces astrocyte reactivity, tau oligomers, and aberrant behavior. Arch Neurosci, 4(2). pii: e44254. PMCID: PMC5529099
• Bohn KA, Adkins CE, Nounou MI, Lockman PR (2017). Inhibition of VEGF and angiopoietin-2 to reduce brain metastases of breast cancer burden. Front Pharmacol, 8:193. PMCID: PMC5387068
• Terrell-Hall TB, Ammer AG, Griffith JI, Lockman PR (2017). Permeability across novel microfluidic blood-tumor barrier model. Fluids Barriers CNS, 14(1):3. PMCID: PMC5260004
• Venishetty VK, Geldenhuys WJ, Terrell-Hall TB, Griffith JIG, Sondag GR, Safadi FF, Lockman PR (2017). Identification of novel agents for the treatment of brain metastases of breast cancer. Curr Cancer Drug Targets, 17(5):479-485. PMCID: PMC5438904
• Mittapalli RK, Adkins CE, Bohn KA, Mohammad AS, Lockman JA, Lockman PR (2017). Quantitative fluorescence microscopy measures vascular pore size in primary and metastatic brain tumors. Cancer Res, 77(2):238-246. PMCID: PMC5267930

[2016]

• Nounou MI, Adkins CE, Rubinchik E, Terrell-Hall TB, Afroz M, Vitalis T, Gabathuler R, Tian MM, Lockman PR (2016). Anti-cancer antibody tastuzumab-melanotransferrin conjugate (BT2111) for the treatment of metastatic HER2+ breast cancer tumors in the brain: an in-vivo study. Pharm Res, 33(12):2930-2942. PMCID: PMC5267937
• Lyle LT, Lockman PR, Adkins CE, Mohammad AS, Sechrest E, Hua E, Palmieri D, Liewehr DJ, Steinberg SM, Kloc W, Izycka-Swieszewska E, Duchnowska R, Nayyar N, Brastianos PK, Steeg PS, Gril B (2016). Alterations in pericyte subpopulations are associated with elevated blood-tumor barrier permeability in experimental brain metastasis of breast cancer. Clin Cancer Res, 22(21):5287-5299. PMCID: PMC5093086
• Bohn KA, Adkins CE, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Shah N, Dolan EL, Nounou MI, Lockman PR (2016). Semi-automated rapid quantification of brain vessel density utilizing fluorescent microscopy. J Neurosci Methods, 270:124-131. PMCID: PMC4981522
• Adkins CE, Mohammad AS, Terrell-Hall TB, Dolan EL, Shah N, Sechrest E, Griffith J, Lockman PR (2016). Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer. Clin Exp Metastasis, 33(4):373-83. PMCID: PMC4804888

[2015]

• Adkins CE, Nounou MI, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Jagannathan R, Lockman PR. A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier.Cancer Prev Res (Phila) 2015 Jan; 8(1):68-76. PMID:PMC4311570.
• Adkins CE, Nounou MI, Hye T, Mohammad AS, Terrell-Hall TB, Mohan NK, Eldon MA, Hoch U, Lockman PR. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. BMC Cancer 2015 Oct; 15:685. PMCID: PMC4604629.
• Geldenhuys WJ, Mohammad AS, Adkins CE, Lockman PR. Molecular determinants of blood-brain barrier permeation. Ther Deliv 2015; 6(8):961-71. PMCID: PMC4675962 [Available on 2016-08-25].
• Puhalla S, Elmquist W, Freyer D, Kleinberg L, Adkins C, Lockman P, McGregor J, Muldoon L, Nesbit G, Peereboom D, Smith Q, Walker S, Neuwelt E. Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol 2015 May; 17(5):639-51. PMCID: PMC4482864.
• Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP,Lockman P, Bai S. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res 2015 Jun; 32(6):2003-14. PMCID: PMC4520542.
• Adkins CE, Nounou MI, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Jagannathan R, Lockman PR. A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier.Cancer Prev Res (Phila) 2015 Jan; 8(1): 68-76. PMCID: PMC4311570
• Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro Oncol 2015 Feb; 17(2): 289-95. PMCID: PMC4288517

[2014]

• Cain J, Conway JM, DiVall MV, Erstad BL, Lockman PR, Ressler JC, Schwartz AH, Stolte S, Nemire RE. Report of the 2013-2014 Academic Affairs Committee. Am J Pharm Educ 2014 Dec; 78(10):S23. PMCID: PMC4315223
• Cain J, Campbell T, Congdon HB, Hancock K, Kaun M, Lockman PR, Evans RL. Complex issues affecting student pharmacist debt. Am J Pharm Educ 2014 Sep; 78(7):131. PMCID: PMC4174373
• El-Habashy SE, Nazief AM, Adkins CE, Wen MM, El-Kamel AH, Hamdan AM, Hanafy AS, Terrell TO, Mohammad AS, Lockman PR, Nounou MI. Novel treatment strategies for brain tumors and metastases. Pharm Pat Anal 2014 May; 3(3):279-96. PMCID: PMC4465202

Recent Scientific Awards

Patent. Lockman PR. "Microfluiduc Device" (2018) Provisional Patent. Patent application for Microfluidic Device (WVU Ref. 2018-018) (Our Ref. WVU 3012-PROV)
Invited Talk; USF & FAMU 2018 Nano-Bio Collaborative International Conference (2018)
TTUHSC President’s Young Investigator Research Award (2009)
TTUHSC School of Pharmacy, Distinguished Alumni Award; Excellence in Research (2010)
Invited Talk; Gordon Research Conference: Barriers of the CNS (2010): Drug delivery to metastatic brain tumors. Colby-Sawyer College, New Hampshire.
Invited Talk; Does Chemotherapy Reach Effective Concentrations for the Treatment of Brain Metastases of Breast Cancer? Medical Rounds – London Health Sciences Center. Invited Seminar and Discussion. London  Ontario, Canada
Invited Talk; Breast Cancer Center of Excellence, Invited Panelist and speaker National Breast Cancer Coalition Fund, Annual Advocacy Training Conference, Washington DC.(2009)
Invited Talk; Challenges and Opportunities to Deliver Drugs in Brain Metastases of Breast Cancer, Invited Seminar, MD Anderson Houston TX (2009)
Invited Talk; Workshop on Drug Delivery in Parkinson’s Disease; Circumventing the Blood-brain barrier (2008):Michael J. Fox Foundation and the Kinetics foundation. San Francisco, CA. 
 
Recent Educational Awards
American Association of Colleges of Pharmacy; Innovations in Teaching Award (2007)
Texas Higher Education Coordinating Board Star Award Finalist (2009)
TTUHSC President’s Excellence in Teaching Award (2008)
P3 Teacher of the Year; Texas Tech University HSC, SOP (2005, 2006, 2007, 2008)
P3 Teaching Team of the Year; Texas Tech University HSC, SOP (2005, 2006, 2007)
P1 Teaching Team of the Year; Texas Tech University HSC, SOP (2004)

Teaching: Clinical Toxicology, Anatomy and Pharmacology

 

 

Dr. Lockman earned his B.S. in Nursing from West Texas A&M University, after which he practiced in intensive care, clinical toxicology and emergency medicine, then went on to earn his Ph.D. (Pharmaceutical Sciences) at Texas Tech University Health Sciences Center. Dr. Lockman was an Associate Professor and Associate Dean for Outcomes Assessment and Accreditation at Texas Tech University before transitioning to West Virginia University. Currently, Dr. Lockman is the Douglas Glover Endowed Chair of Basic Pharmaceutical Sciences at West Virginia University School of Pharmacy. He also serves as the Associate Director for Translational Research at the Mary Babb Randolph Cancer Center. Dr. Lockman’s primary research focus is on understanding why chemotherapy has limited distribution, and ultimately fails in brain metastases of breast cancer. 
 

Other organizations that Dr. Lockman is affiliated with

https://neuroscience.wvu.edu/

http://www.wvctsi.org/

http://wvucancer.org/research/

Breast Cancer

Research Interests
Chemotherapy distribution into brain tumors and metastases
Nanoparticle drug delivery to brain
Effects of nicotine and or smoking on drug distribution
 
Recent and Current Funding
biOasis; Drug Company Contract  “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer; Survival Project”
National Cancer Institute, National Institutes of Health, Bethesda, MD. 1R01CA166067-01A1 “Prevention and Treatment of Brain Micro-metastases of Breast Cancer”
NEKTAR Therapeutics; Drug company contract “Pharmacokinetics and efficacy of NEKTAR-102 in brain metastases of breast cancer”
biOasis; drug company contract “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer”
Department of Defense, Breast Cancer Research Program. #BC096887. Cationic Chemotherapeutics to Penetrate Both the Blood-Brain Barrier and Brain Metastasis of Breast Cancer Cells via the Choline Transporter.
Department of Defense, Breast Cancer Research Program. # BC050006. Blood-Tumor Barrier Characterization and Nanoparticle Drug Delivery in Brain Metastasis of Breast Cancer.
Microtransponder; Medical Device Grant “Feasibility of microstimulation for targeted BBB disruption.” 
Minority Health Research and Education Grant program. State of Texas Board of Higher Education; Minority Health Research and Education Grant. Innovations in Competency Education: Strengthening the Pipeline.
National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD. U19 MH069059-01. Development of Novel Treatments for Nicotine Addiction.”